Department of Infectious Diseases, Walter Reed Army Medical Center, Washington, DC, USA.
J Clin Virol. 2011 Feb;50(2):167-70. doi: 10.1016/j.jcv.2010.10.016. Epub 2010 Nov 19.
Adenovirus infection is a serious and often fatal complication in hematopoietic stem cell transplant patients. There are currently no FDA-approved therapies for adenovirus infection, with only anecdotal, off-label uses described for a variety of anti-viral agents or immune therapies. We report the first case of successful eradication of disseminated adenovirus infection by the novel antiviral agent CMX001 in a severely immunocompromised pediatric stem cell transplant recipient following failure to respond to intravenous cidofovir. Complete clinical and virologic response was documented; virologic and pharmacokinetic data are reported. CMX001 is a promising new oral antiviral agent under development for the prophylaxis and treatment of severe infections caused by double-stranded DNA viruses including adenovirus in immunocompromised patients.
腺病毒感染是造血干细胞移植患者中一种严重且常常致命的并发症。目前尚无获得 FDA 批准的腺病毒感染治疗方法，只有各种抗病毒药物或免疫疗法的传闻、超适应证使用的描述。我们报告首例严重免疫功能低下的儿科造血干细胞移植受者在静脉注射更昔洛韦治疗失败后，新型抗病毒药物 CMX001 成功清除播散性腺病毒感染的病例。完全临床和病毒学应答得到证实；报告了病毒学和药代动力学数据。CMX001 是一种有前途的新型口服抗病毒药物，正在开发用于预防和治疗免疫功能低下患者由双链 DNA 病毒（包括腺病毒）引起的严重感染。
